Press Releases

See the latest Press Releases from Isoray.

IsoRay Announces Signing of Research Funding with Ochsner Clinic Foundation to Support Brain Cancer Treatment Research

May 30, 2018

IsoRay Continues to Support Innovative Techniques in Brain Cancer Treatment RICHLAND, Wash., May 30, 2018 (GLOBE ...

IsoRay Announces Participation at the American Urological Association’s 2018 Annual Meeting, May 18-21, 2018

May 16, 2018

Key Presentation on Prostate Cancer: “Survivor Debate: Low-Intermediate Risk Prostate Cancer” will Feature Noted ...

IsoRay Announces the First Disposable Delivery System for Custom Intra-operative Strands for Prostate Cancer Treatment

May 11, 2018

RICHLAND, Wash., May 11, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company ...

IsoRay Announces Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Third Quarter-Over-Third Quarter Increase

May 3, 2018

Fifth Consecutive Quarter of Year-Over-Year Revenue Increases RICHLAND, Wash., May 03, 2018 (GLOBE NEWSWIRE) -- ...

IsoRay to Present at the 3rd Annual Disruptive Growth & Healthcare Conference hosted by RHK Capital

May 2, 2018

NEW YORK, NY, May 02, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and ...

IsoRay Announces Third Quarter Fiscal 2018 Earnings Conference Call

April 26, 2018

RICHLAND, Wash., April 26, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical ...

IsoRay Announces Preliminary Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Year-over-Year Increase

April 18, 2018

RICHLAND, Wash, April 18, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company ...

IsoRay Announces Second Quarter Fiscal 2018 Revenue of $1.54 Million, 50% Second Quarter-Over-Second Quarter Increase

February 8, 2018

Fourth Consecutive Quarter of Year-Over-Year Revenue Increases RICHLAND, Wash., Feb. 08, 2018 (GLOBE NEWSWIRE) ...

IsoRay Announces Study Published in Cureus entitled, “Resection Cavity Contraction Effects in the Use of Radioactive Sources (1-25 versus Cs‑131) for Intra-Operative Brain Implants”

February 8, 2018

Study Demonstrates “Resection Cavity Contractions Affects Cs-131 Dose Distribution Significantly Less than that of ...

IsoRay Announces Second Quarter Fiscal 2018 Earnings Conference Call

January 31, 2018

RICHLAND, Jan. 31, 2018 (GLOBE NEWSWIRE) -- - IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical ...

IsoRay Announces Preliminary Second Quarter F2018 Revenue of $1.54 Million, 50% Year-over-Year Increase

January 24, 2018

Revenue Increase Driven by Increasing Traction of New Sales Strategies in Prostate Brachytherapy RICHLAND, Wash, ...

IsoRay Announces Case Report Publication Discussing Focal Radiation Treatment of Brain Metastases with Cesium-131

January 9, 2018

Possible Evidence of Paradigm Shift in the Radiation Treatment of Cancers Afflicting the Brain RICHLAND, Wash.,, ...

Media & Public Relations Contact

If you have questions or need help, please contact Sharon Schultz:

Sharon Schultz
Public and Media Relations

<a href="https://isoray.wufoo.com/forms/q1yne4by0qsm7ek/" target="_blank" rel="noopener noreferrer">Fill out my Wufoo form!</a>

Our Management Team

Learn more about our experienced
management team who are focused
on the growth and innovation of Isoray.

Board of Directors

Find out more about our Board of Directors,
Committees and the Governance
of the company.

Our Management Team

Learn more about our experienced
management team who are focused
on the growth and innovation of Isoray.

Board of Directors

Find out more about our Board of Directors,
Committees and the Governance
of the company.

Press Releases

IsoRay Announces Signing of Research Funding with Ochsner Clinic Foundation to Support Brain Cancer Treatment Research

IsoRay Announces Participation at the American Urological Association’s 2018 Annual Meeting, May 18-21, 2018

IsoRay Announces the First Disposable Delivery System for Custom Intra-operative Strands for Prostate Cancer Treatment

IsoRay Announces Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Third Quarter-Over-Third Quarter Increase

IsoRay to Present at the 3rd Annual Disruptive Growth & Healthcare Conference hosted by RHK Capital

IsoRay Announces Third Quarter Fiscal 2018 Earnings Conference Call

IsoRay Announces Preliminary Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Year-over-Year Increase

IsoRay Announces Second Quarter Fiscal 2018 Revenue of $1.54 Million, 50% Second Quarter-Over-Second Quarter Increase

IsoRay Announces Study Published in Cureus entitled, “Resection Cavity Contraction Effects in the Use of Radioactive Sources (1-25 versus Cs‑131) for Intra-Operative Brain Implants”

IsoRay Announces Second Quarter Fiscal 2018 Earnings Conference Call

IsoRay Announces Preliminary Second Quarter F2018 Revenue of $1.54 Million, 50% Year-over-Year Increase

IsoRay Announces Case Report Publication Discussing Focal Radiation Treatment of Brain Metastases with Cesium-131

Media & Public Relations Contact

Our Management Team

Board of Directors

Our Management Team

Board of Directors

Patients & Families

Doctors & Clinicians

Our company

Patients & Families

Doctors & Clinicians

Our Company